The Daily Byte
Breaking
Welcome to The Daily Byte — real stories from across Pakistan.
Saturday, 21 November 2026 · Pakistan

The Daily Byte

Stories from Pakistan that deserve to be heard
Minor UK News

MHRA launches women's health evidence programme

By aminah ·16 Nov 2026 ·3 min read
A female scientist in a lab coat working with a pipette in a medical research laboratory

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new Women’s Health Programme to close long-standing gaps in the evidence on how medicines and medical devices affect women.

The programme was launched today, Monday 16 November, and announced at the inaugural DIA-MHRA Global Summit in London, held on 16 and 17 November as part of London Life Sciences Week. It runs from 2026 to 2030 and is the first part of a wider MHRA initiative to address health inequalities under its Strategy to 2030.

The evidence gap

Women make up 51 per cent of the population, but they have historically been underrepresented in clinical research. An MHRA analysis of all 4,616 UK clinical trial applications submitted between 2019 and 2023 found that pregnant women were represented in just 1.1 per cent of trials, while breastfeeding women were represented in 0.6 per cent.

The regulator says the gaps also cover conditions specific to women, as well as conditions that present differently or disproportionately in women. Because factors such as biology, age, pregnancy and other health conditions can affect how people respond to a medicine or device, the lack of evidence limits the information available to patients and prescribers.

What the programme will do

The Women’s Health Programme aims to bring together patients, researchers, healthcare professionals and industry to strengthen the evidence available, while maintaining safety, quality and effectiveness standards. It will explore how better data and scientific advances can more accurately reflect women’s needs, and support innovation in women’s health technology so promising products can reach patients earlier.

The programme was shaped with patient input through the MHRA’s Patient and Public Community and a focus group delivered by the Patients Association. It is the MHRA’s regulatory contribution to the government’s renewed Women’s Health Strategy for England, published in April 2026, and corresponding work in Scotland, Wales and Northern Ireland.

Women’s health is also a growing area for innovation. The UK’s FemTech sector already has an annual turnover of nearly £300 million, with technologies being developed across reproductive health, long-term conditions and healthy ageing.

What ministers and the regulator said

Women’s Health Minister Baroness Gillian Merron said: “For too long, women’s health has been overlooked. Women make up more than half of our population, yet they have been underrepresented in the research that shapes the medicines and devices they rely on.” She said the programme, together with the renewed Women’s Health Strategy, would mean better evidence, better treatments and a health system that listens to women.

MHRA Chief Executive Lawrence Tallon said closing the gaps in understanding how the risks and benefits of medicines and medical devices differ for women was both a challenge and a huge opportunity, adding that better evidence could support researchers and innovators and create opportunities for healthcare better tailored to women’s needs.

The MHRA will host a webinar on Wednesday 9 December, from 11am to 12pm, introducing the programme and setting out its plans to strengthen evidence, support innovation and improve health outcomes for women.

Sources: GOV.UK; Traders Union.